{"filing":{"accession_number":"0001628280-26-051852","cik":"0001818331","ticker":"WGSWW","company_name":"GeneDx Holdings Corp.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"wgs-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818331/000162828026051852/wgs-20260803.htm"},"events":[{"id":23442,"run_id":21193,"accession_number":"0001628280-26-051852","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"GeneDx issued a press release on August 3, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $114.4 million, exome and genome volume growth of 32% year-over-year, adjusted gross margin of 70%, and adjusted net income of $0.4 million. The filing explicitly states the company \"issued a press release\" and \"will hold a conference call announcing the Company's financial results,\" with copies of the Press Release and Earnings Presentation furnished as exhibits. This is a standard quarterly earnings release disclosure under Item 2.02.","company_name":"GeneDx Holdings Corp.","ticker":"WGSWW","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23663,"accession_number":"0001628280-26-051852","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"GeneDx issued a press release on August 3, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $114.4 million, exome and genome volume growth of 32% year-over-year, adjusted gross margin of 70%, and adjusted net income of $0.4 million. The filing explicitly states the company \"issued a press release\" and \"will hold a conference call announcing the Company's financial results,\" with copies of the Press Release and Earnings Presentation furnished as exhibits. This is a standard quarterly earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:32:06.514708+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23663,"accession_number":"0001628280-26-051852","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"GeneDx issued a press release on August 3, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $114.4 million, exome and genome volume growth of 32% year-over-year, adjusted gross margin of 70%, and adjusted net income of $0.4 million. The filing explicitly states the company \"issued a press release\" and \"will hold a conference call announcing the Company's financial results,\" with copies of the Press Release and Earnings Presentation furnished as exhibits. This is a standard quarterly earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:32:06.514708+00:00","company_name":"GeneDx Holdings Corp.","ticker":"WGSWW","filing_date":"2026-08-03"}]}